Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol

Journal of the American Society of Nephrology

Volumn 17, Issue 3, 2006, Pages 795-804

  Lopez, Ignacio ^a   Aguilera Tejero, Escolastico ^a   Mendoza, Francisco J ^a   Almaden, Yolanda ^b   Perez, Jose ^a   Martin, David ^c   Rodriguez, Mariano ^b  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; R 568; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; DRUG POTENTIATION; EXTRAOSSEOUS CALCIFICATION; HEART; HISTOPATHOLOGY; KIDNEY; LUNG; MALE; MINERALIZATION; MORTALITY; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; SECONDARY HYPERPARATHYROIDISM; STOMACH; SURVIVAL; UREMIA;

EID: 33645458980     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005040342     Document Type: Article

References (39)

1. Giachelli CM: Vascular calcification mechanisms. J Am Soc Nephrol 15: 2959-2964, 2004
2. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39: 695-701, 2002
3. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000
4. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: 1014-1021, 2000
5. Vattikuti R, Towler DA: Osteogenic regulation of vascular calcification: An early perspective. Am J Physiol Endocrinol Metab 286: E686-E696, 2004
6. Proudfoot D, Shanahan CM: Biology of calcification in vascular cells: Intima versus media. Herz 26: 245-251, 2001
7. Chen NX, Moe SM: Vascular calcification in chronic kidney disease. Semin Nephrol 24: 61-68, 2004
8. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
9. Tan AU Jr, Levine BS, Mazess RB, Kyllo DM, Bishop CW, Knutson JC, Kleinman KS, Coburn JW: Effective suppression of parathyroid hormone by 1 alpha-hydroxyvitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 51: 317-323, 1997
10. Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 42: 1191-1198, 1992
11. McCullough PA, Sandberg KR, Dumler F, Yanez JE: Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: A systematic review. J Nephrol 17: 205-215, 2004
12. Merke J, Hoffmann W, Goldschmidt D, Ritz E: Demonstration of 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cells in vitro. Calcif Tissue Int 41: 112-114, 1987
13. Inoue T, Kawashima H: 1,25-Dihydroxyvitamin D3 stimulates 45Ca2+-uptake by cultured vascular smooth muscle cells derived from rat aorta. Biochem Biophys Res Commun 152: 1388-1394, 1988
14. Jono S, Nishizawa Y, Shioi A, Morii H: 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 98: 1302-1306, 1998
15. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 95: 4040-4045, 1998
16. Fox J, Lowe SH, Conklin RL, Nemeth EF: The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrine 10: 97-103, 1999
17. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J: Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 57: 50-58, 2000
18. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100: 2977-2983, 1997
19. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N: NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53: 448-453, 1998
20. Ishii H, Wada M, Furuya Y, Nagano N, Nemeth EF, Fox J: Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 26: 175-182, 2000
21. Price PA, Faus SA, Williamson MK: Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 20: 317-327, 2000
22. Price PA, June HH, Buckley JR, Williamson MK: Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21: 1610-1616, 2001
23. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A: Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15: 770-779, 2004
24. Naveh-Many T, Rahamimov R, Livni N, Silver J: Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 96: 1786-1793, 1995
25. Slatopolsky E, Finch J, Ritter C, Takahashi F: Effects of 19-nor-1,25(Oh)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis 32: S40-S47, 1998
26. Slatopolsky E, Cozzolino M, Finch JL: Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1α-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int 62: 1277-1284, 2002
27. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
28. Jono S, Nishizawa Y, Shioi A, Morii H: 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 98: 1302-1306, 1998
29. Fraser JD, Price PA: Induction of matrix Gla protein synthesis during prolonged 1,25-dihydroxyvitamin D3 treatment of osteosarcoma cells. Calcif Tissue Int 46: 270-279, 1990
30. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature 386: 78-81, 1997
31. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL: High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 93: 2393-2402, 1994
32. Moe SM, Reslerova M, Ketteler M, O'Neill K, Duan D, Koczman J, Westenfeld R, Jahnen-Dechent W, Chen NX: Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 67: 2295-2304, 2005
33. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1-S201, 2003
34. Reed J, Keightley G, Blumenthal S, Bradley C, LaBrecque T, Turner S, Chertow G: The Control Study: Enhanced achievement of NKF-K/DOQI bone metabolism and disease targets using cinacalcet HCl (Sensipar) [Abstract]. J Am Soc Nephrol 15: 280A-281A, 2004
35. Chertow GM, Corpier C, Zeig S, Stegman, M, Lynn R, Abu-Alfa AK, Faddem S, Tucker K, Shapiro W, Sugihara J, LaBrecque J, Bradley C, Turner SA, Block GA: Preliminary results from target: Treatment strategies to achieve recommended K/DOQI goals in ESRD patients on cinacalcet [Abstract]. J Am Soc Nephrol 15: 863A, 2004
36. Farzaneh-Far A, Proudfoot D, Weissberg PL, Shanahan CM: Matrix Gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun 277: 736-740, 2000
37. Shalhoub V, Shatzen E, Lacey D, Martin D: Calcification of bovine vascular smooth muscle cells in vitro by calcitriol and paricalcitol but not the calcimimetic Nps R-568 [Abstract]. J Am Soc Nephrol 15: 281A + poster, 2004
38. Quarles LD, Hartle JE 2nd, Siddhanti SR, Guo R, Hinson TK: A distinct cation-sensing mechanism in Mc3t3-E1 osteoblasts functionally related to the calcium receptor. J Bone Miner Res 12: 393-402, 1997
39. Pattaragarn A, Fox J, Alon US: Effect of the calcimimetic Nps R-467 on furosemide-induced nephrocalcinosis in the young rat. Kidney Int 65: 1684-1689, 2004